Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24184661 | 0.93 | NQO1 (0.50) | NQO1ADRA2AP2RY6TDP1TSHR | |
| SCHEMBL4195537 | 0.89 | RELA (0.59) | NQO1ADRA2AP2RY6KMT2AALDH1A1 | |
| SCHEMBL4195532 | 0.89 | RELA (0.59) | NQO1ADRA2AP2RY6KMT2AALDH1A1 | |
| SCHEMBL9362384 | 0.84 | CYP2C9 (0.51) | P2RY6TSHRALDH1A1CYP1A2MIF | |
| SCHEMBL230798 | 0.82 | NQO1 (0.56) | NQO1ADRA2ATDP1TSHRKMT2A | |
| SCHEMBL3085833 | 0.80 | CYP3A4 (0.49) | NQO1ADRA2AP2RY6TDP1KMT2A | |
| SCHEMBL17519938 | 0.79 | P2RY6 (0.52) | NQO1ADRA2AP2RY6KMT2AALDH1A1 | |
| SCHEMBL2367473 | 0.79 | P2RY6 (0.47) | P2RY6CYP1A2MIFMAPT | |
| SCHEMBL11852926 | 0.79 | P2RY6 (0.47) | P2RY6TSHRKMT2AALDH1A1MIF | |
| SCHEMBL24184660 | 0.78 | CYP1A2 (0.46) | P2RY6TSHRALDH1A1CYP1A2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2024-12-19 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-112955433-A | Compounds, compositions and methods for selectively inhibiting beta-glucuronidase and reducing side effects associated with drug therapy-induced diarrhea | 赛伯克斯股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3710003-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING Beta- -GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | Symberix, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-7022702-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | TRIAD THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | DERMIRA (CANADA), INC. | 2003-05-22 | — | — | US | disclosed |
| US-5310724-A | Pre- and postemergence; plant growth regulators | FMC CORPORATION (US) | 1994-05-10 | — | — | US | disclosed |
| US-5108486-A | Herbicides | KANAGAWA CHEMICAL LABORATORY, LTD. (JP) | 1992-04-28 | — | — | US | disclosed |
| US-4339455-A | 1-(3-Pyridyl)-2,2,2-trihaloethyl compounds and fungicidal compositions containing the same | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1982-07-13 | — | — | US | disclosed |
| US-4189486-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | NQO1 3399/4885ADRA2A 2043/4885P2RY6 278/4885 |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | NQO1 3723/4885ADRA2A 1214/4885P2RY6 1187/4885 |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND1, CCND3 | NQO1 1349/4885ADRA2A 818/4885P2RY6 2188/4885 |
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, ENGASE | NQO1 824/4885ADRA2A 894/4885P2RY6 1893/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | NQO1 835/4885ADRA2A 903/4885P2RY6 1961/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | NQO1 3723/4885ADRA2A 1214/4885P2RY6 1187/4885 |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND3, ACIN1 | NQO1 440/4885ADRA2A 364/4885P2RY6 3463/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | NQO1 1251/4885ADRA2A 1089/4885P2RY6 1998/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | NQO1 3723/4885ADRA2A 1214/4885P2RY6 1187/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | NQO1 1298/4885ADRA2A 687/4885P2RY6 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.